Sandoz Unveils Further Biosimilars Investment
Plans To Spend Around $90m To Build Technical Development Center In Slovenia
On the back of recently-announced initiatives and alliances to bolster its biosimilars business ahead of its upcoming spinoff from parent company Novartis, Sandoz has revealed a further investment of around $90m to construct a technical development center in Slovenia.
